Celekoksib

Celekoksib
Klinički podaci
Prodajno ime	Celebra, Celebrex
Drugs.com	Monografija
Način primene	Oralno
Farmakokinetički podaci
Poluvreme eliminacije	11 h
Izlučivanje	Renalno, fekalno
Identifikatori
CAS broj	169590-42-5
ATC kod	L01XX33 (WHO), M01AH01
PubChem	CID 2662
DrugBank	DB00482
ChemSpider	2562
KEGG	C07589
ChEBI	CHEBI:3520
ChEMBL	CHEMBL118
Hemijski podaci
Formula	C17H14F3N3O2S
Molarna masa	381,372
	SMILES CC1=CC=C(C=C1)C1=CC(=NN1C1=CC=C(C=C1)S(N)(=O)=O)C(F)(F)F; ;
	InChI InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25) ; Key:RZEKVGVHFLEQIL-UHFFFAOYSA-N ;
Fizički podaci
Tačka topljenja	158 °C (316 °F)

Celekoksib je COX-2 selektivni nesteroidni anti-inflamatorni lek. Jedno od imena pod kojima se prodaje je Celebrex.

Hemijske osobine

Celekoksib je organsko jedinjenje, koje sadrži 17 atoma ugljenika i ima molekulsku masu od 381,372 Da.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Osobine

Osobina	Vrednost
Broj akceptora vodonika	3
Broj donora vodonika	1
Broj rotacionih veza	4
Particioni koeficijent^[9] (ALogP)	4,4
Rastvorljivost^[10] (logS, log(mol/L))	-6,4
Polarna površina^[11] (PSA, Å²)	86,4

Reference

^ Malhotra S, Shafiq N, Pandhi P. Malhotra, S.; Shafiq, N.; Pandhi, P. (2004 Mar 23). „COX-2 inhibitors: a CLASS act or Just VIGORously promoted”. MedGenMed. 6 (1): 6. PMC 1140734 . PMID 15208519. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. Silverstein, Fred E.; Faich, Gerald; Goldstein, Jay L.; Simon, Lee S.; Pincus, Theodore; Whelton, Andrew; Makuch, Robert; Eisen, Glenn; Agrawal, Naurang M.; Stenson, William F.; Burr, Aimee M.; Zhao, William W.; Kent, Jeffrey D.; Lefkowith, James B.; Verburg, Kenneth M.; Geis, G. Steven (2000 Sep 13). „Gastrointestinal Toxicity with Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis”. JAMA. 284 (10): 1247—55. PMID 10979111. doi:10.1001/jama.284.10.1247. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Solomon, Scott D.; McMurray, John J.V.; Pfeffer, Marc A.; Wittes, Janet; Fowler, Robert; Finn, Peter; Anderson, William F.; Zauber, Ann; Hawk, Ernest; Bertagnolli, Monica (2005 Mar 17). „Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention”. N Engl J Med. 352 (11): 1071—80. PMID 15713944. doi:10.1056/NEJMoa050405. Проверите вредност парамет(а)ра за датум: |date= (помоћ) Feb 15.
^ Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown RM: Celecoxib compared with sustained-release paracetamol for osteoarthritis: a series of n-of-1 trials. Rheumatology (Oxford). 46 (1): 135-40 Jun 15. PMID 16777855
^ Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET. Bertagnolli, Monica M.; Eagle, Craig J.; Zauber, Ann G.; Redston, Mark; Solomon, Scott D.; Kim, Kyungmann; Tang, Jie; Rosenstein, Rebecca B.; Wittes, Janet; Corle, Donald; Hess, Timothy M.; Woloj, G. Mabel; Boisserie, Frédéric; Anderson, William F.; Viner, Jaye L.; Bagheri, Donya; Burn, John; Chung, Daniel C.; Dewar, Thomas; Foley, T. Raymond; Hoffman, Neville; MacRae, Finlay; Pruitt, Ronald E.; Saltzman, John R.; Salzberg, Bruce; Sylwestrowicz, Thomas; Gordon, Gary B.; Hawk, Ernest T. (2006 Aug 31). „Celecoxib for the prevention of sporadic colorectal adenomas”. N Engl J Med. 355 (9): 873—84. PMID 16943400. doi:10.1056/NEJMoa061355. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Sandberg, Mia; Yasar, Ümit; Strömberg, Patrik; Höög, Jan-Olov; Eliasson, Erik (2002 Oct). „Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase”. Br J Clin Pharmacol. 54 (4): 423—9. PMC 1874434 . PMID 12392591. doi:10.1046/j.1365-2125.2002.01660.x. Проверите вредност парамет(а)ра за датум: |date= (помоћ)
^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126.
^ Wishart, D. S.; Knox, C.; Guo, A. C.; Cheng, D.; Shrivastava, S.; Tzur, D.; Gautam, B.; Hassanali, M. (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o.
^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e.